# Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis

> **NCT02480946** · PHASE1 · COMPLETED · sponsor: **Modern Biosciences Ltd** · enrollment: 105 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** MBS2320
- **DRUG:** Placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT02480946
- **Lead sponsor:** Modern Biosciences Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2017-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02480946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02480946, "Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02480946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*